In 2006, Kern MA and colleagues added selective cyclooxygenase-2 inhibitor Meloxicam to a surgical resected PCLS model of HCC and confirmed the antitumor effect of COX-2 inhibition with significantly increased tumor cell apoptosis and reduced tumor proliferation. Here, PTGS2 is linked to hepatocellular carcinoma.